Status:
COMPLETED
PET Scan to Determine Areas of Blood Flow and Activity in the Hearts of Patients With Heart Disease Taking Beta-Blockers
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Heart Failure, Congestive
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The human heart is divided into four chambers. One of the four chambers, the left ventricle, is the chamber mainly responsible for pumping blood out of the heart into the circulation. Diseases of the ...
Detailed Description
Deterioration in left ventricular function, which is characteristic in patients with congestive heart failure, appears to be a multifactorial process. Beta-blockers appear to reverse the deterioration...
Eligibility Criteria
Left ventricular ejection fraction by radionuclide angiography of less than or equal to 40%.
New York Heart Association class II, III or IV symptoms on standard heart failure medications which my include digoxin, diuretics and angiotensin converting enzyme inhibitors for at least one month prior to enrollment.
Ischemic cardiomyopathy if enzymes document an MI or 70% or greater stenosis in one major vessel.
Dilated cardiomyopathy-if no coronary disease.
No pregnant or lactating women.
No women of child-bearing age not on proven birth control.
No severe hepatic or renal disease.
No diabetes mellitus or fasting glucose greater than or equal to 120 mg/dl.
No primary valvular heart disease.
No PTCA or CABG within 3 months of enrollment.
No history of myocardial infarction or unstable angina within past 2 months.
No resting heart rate less than 60 bpm.
No A-V block greater than 1 degree block without pacemaker.
No severe ETOH abuse within 6 months of enrollment.
No severe bronchospasm.
Key Trial Info
Start Date :
January 1 1994
Trial Type :
INTERVENTIONAL
End Date :
March 1 2001
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00001402
Start Date
January 1 1994
End Date
March 1 2001
Last Update
March 4 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, United States, 20892